EGFR and colorectal carcinoma: Combination therapy is the best approach to overcome acquired therapeutic resistance and these commonly target upstream RTKs (especially EGFR reactivation in CRC), mediators of the MAPK cascade SHP2/SOS, adaptive alterations of RAS genes, and activation of multiple downstream pathways (Figure 3).